These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 23536434)
1. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Wardell SE; Nelson ER; Chao CA; McDonnell DP Clin Cancer Res; 2013 May; 19(9):2420-31. PubMed ID: 23536434 [TBL] [Abstract][Full Text] [Related]
2. A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance. Ma Y; Preet A; Tomita Y; De Oliveira E; Zhang L; Ueda Y; Clarke R; Brown M; Rosen EM Oncotarget; 2015 Dec; 6(38):40388-404. PubMed ID: 26575173 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817 [TBL] [Abstract][Full Text] [Related]
4. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells. Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334 [TBL] [Abstract][Full Text] [Related]
5. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats. Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711 [TBL] [Abstract][Full Text] [Related]
6. USP36 promotes tumorigenesis and tamoxifen resistance in breast cancer by deubiquitinating and stabilizing ERα. Zhuang T; Zhang S; Liu D; Li Z; Li X; Li J; Yang P; Zhang C; Cui J; Fu M; Shen F; Yuan L; Zhang Z; Su P; Zhu J; Yang H J Exp Clin Cancer Res; 2024 Aug; 43(1):249. PubMed ID: 39215346 [TBL] [Abstract][Full Text] [Related]
7. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer. Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581 [TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts. Cottu P; Bièche I; Assayag F; El Botty R; Chateau-Joubert S; Thuleau A; Bagarre T; Albaud B; Rapinat A; Gentien D; de la Grange P; Sibut V; Vacher S; Hatem R; Servely JL; Fontaine JJ; Decaudin D; Pierga JY; Roman-Roman S; Marangoni E Clin Cancer Res; 2014 Aug; 20(16):4314-25. PubMed ID: 24947930 [TBL] [Abstract][Full Text] [Related]
9. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer. Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988 [TBL] [Abstract][Full Text] [Related]
10. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Howell SJ; Johnston SR; Howell A Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597 [TBL] [Abstract][Full Text] [Related]
11. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation. Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413 [TBL] [Abstract][Full Text] [Related]
12. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models. Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569 [TBL] [Abstract][Full Text] [Related]
13. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112 [TBL] [Abstract][Full Text] [Related]
15. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast. Pickar JH; Komm BS Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836 [TBL] [Abstract][Full Text] [Related]
16. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619 [TBL] [Abstract][Full Text] [Related]
17. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells. Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451 [TBL] [Abstract][Full Text] [Related]
18. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976 [TBL] [Abstract][Full Text] [Related]
19. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells. Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440 [TBL] [Abstract][Full Text] [Related]
20. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]